Targeted therapy before surgery for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has a specific change called an EGFR mutation.
- Your cancer is at stage II or III, meaning it is in the chest but has not spread to other organs.
- Your cancer can be measured on a CT scan (at least 1 cm).
- You are healthy enough to undergo surgery, with good lung function and good performance status (ECOG 0-1).
- You have not received any prior treatment for lung cancer.
- You are at least 18 years old, and if of childbearing potential, you agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.